Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Protein Quality Assessment of Follow-up Formula for Young Children and Ready-to-Use Therapeutic Foods: Recommendations by the FAO Expert Working Group in 2017.

Shivakumar N, Jackson AA, Courtney-Martin G, Elango R, Ghosh S, Hodgkinson S, Xipsiti M, Lee WTK, Kurpad AV, Tomé D.

J Nutr. 2019 Nov 14. pii: nxz250. doi: 10.1093/jn/nxz250. [Epub ahead of print]

PMID:
31724705
2.

Alloactivation of Naïve CD4+CD8-CD25+T Regulatory Cells: Expression of CD8α Identifies Potent Suppressor Cells That Can Promote Transplant Tolerance Induction.

Verma ND, Robinson CM, Carter N, Wilcox P, Tran GT, Wang C, Sharland A, Nomura M, Plain KM, Bishop GA, Hodgkinson SJ, Hall BM.

Front Immunol. 2019 Oct 14;10:2397. doi: 10.3389/fimmu.2019.02397. eCollection 2019.

3.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T.

Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.

PMID:
31397221
4.

Adjuvant immunosuppression for paradoxical deterioration in tuberculous meningitis including one case responsive to cyclosporine. A tertiary referral hospital experience.

Ledingham D, El-Wahsh S, Sebire D, Cappelen-Smith C, Hodgkinson SJ, McDougall AJ, Maley M, Cordato DJ.

J Neurol Sci. 2019 Sep 15;404:58-62. doi: 10.1016/j.jns.2019.07.002. Epub 2019 Jul 13.

PMID:
31330455
5.

Trends in acute stroke presentations to an emergency department: implications for specific communities in accessing acute stroke care services.

Bhaskar S, Thomas P, Cheng Q, Clement N, McDougall A, Hodgkinson S, Cordato D.

Postgrad Med J. 2019 May;95(1123):258-264. doi: 10.1136/postgradmedj-2019-136413. Epub 2019 May 16.

PMID:
31097575
6.

Increasing Mental Health Engagement From Primary Care: The Potential Role of Family Navigation.

Godoy L, Hodgkinson S, Robertson HA, Sham E, Druskin L, Wambach CG, Beers LS, Long M.

Pediatrics. 2019 Apr;143(4). pii: e20182418. doi: 10.1542/peds.2018-2418. Epub 2019 Mar 15. Review.

PMID:
30877145
7.

Clot Histopathology in Ischemic Stroke with Infective Endocarditis.

Bhaskar S, Saab J, Cappelen-Smith C, Killingsworth M, Wu XJ, Cheung A, Manning N, Aouad P, McDougall A, Hodgkinson S, Cordato D.

Can J Neurol Sci. 2019 May;46(3):331-336. doi: 10.1017/cjn.2019.8. Epub 2019 Mar 14.

PMID:
30867075
8.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
9.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
10.

Cooking Conditions Affect the True Ileal Digestible Amino Acid Content and Digestible Indispensable Amino Acid Score (DIAAS) of Bovine Meat as Determined in Pigs.

Hodgkinson SM, Montoya CA, Scholten PT, Rutherfurd SM, Moughan PJ.

J Nutr. 2018 Oct 1;148(10):1564-1569. doi: 10.1093/jn/nxy153.

PMID:
30204886
11.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
12.

Factors Associated with Stroke Misdiagnosis in the Emergency Department: A Retrospective Case-Control Study.

Venkat A, Cappelen-Smith C, Askar S, Thomas PR, Bhaskar S, Tam A, McDougall AJ, Hodgkinson SJ, Cordato DJ.

Neuroepidemiology. 2018;51(3-4):123-127. doi: 10.1159/000491635. Epub 2018 Aug 9.

PMID:
30092562
13.

Interleukin-5 Mediates Parasite-Induced Protection against Experimental Autoimmune Encephalomyelitis: Association with Induction of Antigen-Specific CD4+CD25+ T Regulatory Cells.

Tran GT, Wilcox PL, Dent LA, Robinson CM, Carter N, Verma ND, Hall BM, Hodgkinson SJ.

Front Immunol. 2017 Nov 1;8:1453. doi: 10.3389/fimmu.2017.01453. eCollection 2017.

14.

Association of teen mothers' and grandmothers' parenting capacities with child development: A study protocol.

Wilson D, Gross D, Hodgkinson S, Deater-Deckard K.

Res Nurs Health. 2017 Dec;40(6):512-518. doi: 10.1002/nur.21839. Epub 2017 Nov 11.

15.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
16.

Behavioral Health Integration in Health Care Settings: Lessons Learned from a Pediatric Hospital Primary Care System.

Godoy L, Long M, Marschall D, Hodgkinson S, Bokor B, Rhodes H, Crumpton H, Weissman M, Beers L.

J Clin Psychol Med Settings. 2017 Dec;24(3-4):245-258. doi: 10.1007/s10880-017-9509-8.

PMID:
28929269
17.

Cardiac transplant due to metal toxicity associated with hip arthroplasty.

Moniz S, Hodgkinson S, Yates P.

Arthroplast Today. 2017 Mar 11;3(3):151-153. doi: 10.1016/j.artd.2017.01.005. eCollection 2017 Sep.

18.

Changes in Reactivity In Vitro of CD4+CD25+ and CD4+CD25- T Cell Subsets in Transplant Tolerance.

Hall BM, Robinson CM, Plain KM, Verma ND, Tran GT, Nomura M, Carter N, Boyd R, Hodgkinson SJ.

Front Immunol. 2017 Aug 22;8:994. doi: 10.3389/fimmu.2017.00994. eCollection 2017.

19.

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group.

Mult Scler. 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: Mult Scler. 2017 Dec;23(14):NP1.

PMID:
28857680
20.

Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation?

Hardy TA, Young S, Sy JS, Colley AF, Terwindt GM, Ferrari MD, Hayes MW, Hodgkinson S.

J Neurol Neurosurg Psychiatry. 2017 Aug 9. pii: jnnp-2017-316142. doi: 10.1136/jnnp-2017-316142. [Epub ahead of print] No abstract available.

PMID:
28794152
21.

A Brain-Derived Neurotrophic Factor-Based p75NTR Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination.

Gonsalvez DG, Tran G, Fletcher JL, Hughes RA, Hodgkinson S, Wood RJ, Yoo SW, De Silva M, Agnes WW, McLean C, Kennedy P, Kilpatrick TJ, Murray SS, Xiao J.

eNeuro. 2017 Jul 4;4(3). pii: ENEURO.0142-17.2017. doi: 10.1523/ENEURO.0142-17.2017. eCollection 2017 May-Jun.

22.

Cytokines affecting CD4+T regulatory cells in transplant tolerance. III. Interleukin-5 (IL-5) promotes survival of alloantigen-specific CD4+ T regulatory cells.

Hall BM, Plain KM, Tran GT, Verma ND, Robinson CM, Nomura M, Boyd R, Hodgkinson SJ.

Transpl Immunol. 2017 Aug;43-44:33-41. doi: 10.1016/j.trim.2017.06.003. Epub 2017 Jun 23.

PMID:
28652007
23.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

24.

Cytokines affecting CD4+T regulatory cells in transplant tolerance. II. Interferon gamma (IFN-γ) promotes survival of alloantigen-specific CD4+T regulatory cells.

Nomura M, Hodgkinson SJ, Tran GT, Verma ND, Robinson C, Plain KM, Boyd R, Hall BM.

Transpl Immunol. 2017 Jun;42:24-33. doi: 10.1016/j.trim.2017.05.002. Epub 2017 May 6.

25.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
26.

Improving Mental Health Access for Low-Income Children and Families in the Primary Care Setting.

Hodgkinson S, Godoy L, Beers LS, Lewin A.

Pediatrics. 2017 Jan;139(1). pii: e20151175. doi: 10.1542/peds.2015-1175. Epub 2016 Dec 12. Review.

27.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.

PMID:
27810919
28.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28.

PMID:
27683916
29.

Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.

Stam AH, Kothari PH, Shaikh A, Gschwendter A, Jen JC, Hodgkinson S, Hardy TA, Hayes M, Kempster PA, Kotschet KE, Bajema IM, van Duinen SG, Maat-Schieman MLC, de Jong PTVM, de Smet MD, de Wolff-Rouendaal D, Dijkman G, Pelzer N, Kolar GR, Schmidt RE, Lacey J, Joseph D, Fintak DR, Grand MG, Brunt EM, Liapis H, Hajj-Ali RA, Kruit MC, van Buchem MA, Dichgans M, Frants RR, van den Maagdenberg AMJM, Haan J, Baloh RW, Atkinson JP, Terwindt GM, Ferrari MD.

Brain. 2016 Nov 1;139(11):2909-2922. doi: 10.1093/brain/aww217. No abstract available.

30.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
31.

Care of dying adults in the last days of life .

Hodgkinson S, Ruegger J, Field-Smith A, Latchem S, Ahmedzai SH.

Clin Med (Lond). 2016 Jun;16(3):254-8. doi: 10.7861/clinmedicine.16-3-254.

32.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group.

Ann Neurol. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1.

PMID:
27145331
33.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group.

Mult Scler. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.

PMID:
27055805
34.

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.

Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'Maison F, Grammond P, Barnett M, Lechner-Scott J, Alroughani R, Trojano M, Lugaresi A, Granella F, Pucci E, Vucic S; MSBase Study Group.

Eur J Neurol. 2016 Apr;23(4):729-36. doi: 10.1111/ene.12929. Epub 2016 Jan 19.

PMID:
26782663
35.

Care of adults in the last days of life: summary of NICE guidance.

Ruegger J, Hodgkinson S, Field-Smith A, Ahmedzai SH; guideline committee.

BMJ. 2015 Dec 16;351:h6631. doi: 10.1136/bmj.h6631. No abstract available.

PMID:
26676374
36.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
37.

The Effect of Biofeedback as a Psychological Intervention in Multiple Sclerosis: A Randomized Controlled Study.

Mackay AM, Buckingham R, Schwartz RS, Hodgkinson S, Beran RG, Cordato DJ.

Int J MS Care. 2015 May-Jun;17(3):101-8. doi: 10.7224/1537-2073.2014-006.

38.

Induction of antigen specific CD4(+)CD25(+)Foxp3(+)T regulatory cells from naïve natural thymic derived T regulatory cells.

Hall BM, Tran GT, Robinson CM, Hodgkinson SJ.

Int Immunopharmacol. 2015 Oct;28(2):875-86. doi: 10.1016/j.intimp.2015.03.049. Epub 2015 Apr 13.

PMID:
25882104
39.

Strengthening positive coparenting in teen parents: a cultural adaptation of an evidence-based intervention.

Lewin A, Hodgkinson S, Waters DM, Prempeh HA, Beers LS, Feinberg ME.

J Prim Prev. 2015 Jun;36(3):139-54. doi: 10.1007/s10935-015-0388-1.

PMID:
25771911
40.

Effect of three different bariatric obesity surgery procedures on nutrient and energy digestibility using a swine experimental model.

Gandarillas M, Hodgkinson SM, Riveros JL, Bas F.

Exp Biol Med (Maywood). 2015 Sep;240(9):1158-64. doi: 10.1177/1535370214567635. Epub 2015 Feb 23.

41.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: JAMA Neurol. 2015 Aug;72(8):950.

42.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; MSBase Study Group.

Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17.

PMID:
25546031
43.

Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.

Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ.

J Clin Neurosci. 2015 Mar;22(3):598-600. doi: 10.1016/j.jocn.2014.08.016. Epub 2014 Dec 15.

PMID:
25523125
44.

Informed consent and the implications for statutory rape reporting in research with adolescents.

Hodgkinson S, Lewin A, Chang B, Beers L, Silber T.

Am J Bioeth. 2014;14(10):54-5. doi: 10.1080/15265161.2014.947818. No abstract available.

PMID:
25229591
45.

The protective effects of father involvement for infants of teen mothers with depressive symptoms.

Lewin A, Mitchell SJ, Waters D, Hodgkinson S, Southammakosane C, Gilmore J.

Matern Child Health J. 2015 May;19(5):1016-23. doi: 10.1007/s10995-014-1600-2.

PMID:
25102809
46.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
47.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
48.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
49.

Anti-neuronal antibodies associated with a first episode of mania.

Rege S, Hodgkinson SJ.

Aust N Z J Psychiatry. 2014 Aug;48(8):775-7. doi: 10.1177/0004867414536934. Epub 2014 May 30. No abstract available.

PMID:
24878564
50.

Interleukin-12 (IL-12p70) Promotes Induction of Highly Potent Th1-Like CD4(+)CD25(+) T Regulatory Cells That Inhibit Allograft Rejection in Unmodified Recipients.

Verma ND, Hall BM, Plain KM, Robinson CM, Boyd R, Tran GT, Wang C, Bishop GA, Hodgkinson SJ.

Front Immunol. 2014 May 9;5:190. doi: 10.3389/fimmu.2014.00190. eCollection 2014.

Supplemental Content

Loading ...
Support Center